Posted by Michael Wonder on 16 Feb 2021
AstraZeneca, Daiichi Sankyo’s Enhertu scores approval in the UK
17 February 2021 - AstraZeneca and Daiichi Sankyo’s antibody drug conjugate Enhertu has scored a conditional marketing authorisation in the UK for certain breast cancer patients.
The conditional marketing authorisation covers the use of Enhertu (trastuzumab deruxtecan) as a monotherapy for the treatment of adults with unresectable or metastatic HER2 positive breast cancer, who have received two or more prior anti-HER2 based regimens.
